SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo

@article{Roth2009SC68896AN,
  title={SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo},
  author={Patrick Roth and Maria Kissel and Caroline Herrmann and Günter Eisele and Johann Jakob Leban and Michael Weller and Friederike Schmidt},
  journal={Clinical Cancer Research},
  year={2009},
  volume={15},
  pages={6609 - 6618}
}
Purpose: Glioblastomas are among the most lethal neoplasms, with a median survival of <1 year. Modulation of the proteasome function has emerged as a novel approach to cancer pharmacotherapy. Here, we characterized the antitumor properties of SC68896, a novel small molecule proteasome inhibitor. Experimental Design: Different tumor cell lines were tested by crystal violet staining for sensitivity to SC68896, given alone or in combination with death ligands. The molecular mechanisms mediating… Expand
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
TLDR
The study represents the first demonstration that the combination of cediranib with a proteasome inhibitor substantially increases the anti-angiogenic efficacy produced from either agent alone, and synergistically slows glioma tumor growth and extends survival, suggesting a promising treatment which warrants further investigation. Expand
Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines
TLDR
The results suggest that the combination of TRAIL and salinomycin may be a useful tool to overcome TRAIL resistance in glioma cells and may represent a potential drug for treatment of these tumors. Expand
Proteasome inhibition for the treatment of glioblastoma
TLDR
Marizomib is a novel drug that displays strong inhibitory properties on all enzymatic subunits of the proteasome and crosses the blood-brain barrier, making it a potentially very active novel agent against intrinsic brain tumors. Expand
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
TLDR
This mini-review aims to provide an overview of the intricate relationship between p53 and the TRAIL-mediated apoptosis pathway, and to summarize the current approaches of targeting p53 as a therapeutic strategy to sensitize TRAil-induced apoptosis in human cancer cells. Expand
Styryl-cinnamate hybrid inhibits glioma by alleviating translation, bioenergetics and other key cellular responses leading to apoptosis.
TLDR
It is discovered that Styryl-cinnamate hybrid targets glioma by intrinsically triggering metabolite-mediated stress and various oncological circuits alleviated by the potential drug candidate strongly supports the role of such pharmacophores as anticancer drugs. Expand
Inhibitors of Proteinases as Potential Anti-Cancer Agents
TLDR
Inhibitor therapy design is further complicated because different types of cancers utilize diverse proteinases at varying stages of cancer development, and construction of the inhibitor, which should have an impact on tumor progression and metastasis, cannot be done without placing certain proteinase in the proper metabolic context. Expand
Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling
TLDR
Examination of the mechanisms underlying cytotoxicity, selectivity and adjuvant potential of the proteasome inhibitor MG132 in a panel of glioblastoma cells and in normal astrocytes revealed profound and selective toxicity in GBMs, being a potential agent for further testing in animal models of the disease. Expand
Targeting apoptosis pathways in glioblastoma.
TLDR
The alterations affecting the p53 pathway, the BCL-2 protein family, the inhibitor of apoptosis proteins and several growth factor pathways involved in the regulation of programmed cell death are described and possible targets for new therapies within these apoptotic pathways in glioblastomas are defined. Expand
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
TLDR
The 26S proteasome constitutes an essential degradation apparatus involved in the consistent recycling of misfolded and damaged proteins inside cells and is reviewed here in the context of sensitization of malignant gliomas, a tumor type particularly refractory to conventional treatments. Expand
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
TLDR
The ubiquitin-proteasome system is a major pathway for protein degradation that activates macroautophagy, a compensatory protein degradation system, as well as other pro-survival signaling pathways, and inhibition of this pathway sensitizes cancer cells to the anti-proliferative effects of proteasome inhibitors. Expand
...
1
2
...

References

SHOWING 1-10 OF 36 REFERENCES
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
TLDR
It is demonstrated that ritonavir, by inhibiting the chymotrypsin-like activity of the proteasome, has cytostatic and cytotoxic effects on glioma cells, and can induce resistances in vitro. Expand
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
TLDR
This study is the first to demonstrate that bortezomib, at a clinically relevant dose, did not have any effect on the apoptosis and proliferation of malignant gliomas in vivo. Expand
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
TLDR
Examining its antiproliferation, proapoptotic effects using three human glioblastoma multiforme cell lines and five primary GBM explants suggests that PS-341 may be an effective therapy for patients with gliomas. Expand
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
TLDR
Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies by enhancing the antitumor activity of Apo-2L/tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in an intracranial malignant glioma xenograft model in vivo. Expand
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma
TLDR
The constitutive expression of natural caspase inhibitors may play a role in the resistance of these cells to apoptotic stimuli that directly target caspases, including radiochemotherapy and immune-mediated tumor cell lysis. Expand
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
TLDR
The results show that proteasome inhibitors induce time- and dose-dependent cell cycle alterations, growth inhibition, and apoptosis in human myeloma cells irrespective of chromosome 13 deletion. Expand
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
TLDR
TRAIL sensitivity of tumor cell lines is not a reliable predictor for the behavior of primary tumor cells, and the widespread TRAIL resistance in primary glioma cells described here questions the therapeutic clinical benefit of TRAIL as a monotherapeutic agent. Expand
APO2 ligand: a novel lethal weapon against malignant glioma?
TLDR
It is reported that human glioma cell lines preferentially express mRNAs for agonistic death receptors DR4 and DR5 rather than the death‐inhibitory decoy receptors DcR1 and Dcr2, which may be a promising approach for selectively targeting apoptosis to human malignant gliomas cells. Expand
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
TLDR
The present study highlights the important role of DR5 up-regulation in PS-341- induced apoptosis and enhancement of TRAIL-induced apoptosis in human NSCLC cells. Expand
Proteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells
TLDR
The data indicate that proteasome inhibition induces a p21-independent G2/M arrest and p53-independent apoptosis in human malignant glioma cells. Expand
...
1
2
3
4
...